PRONAV Clinical joins EuropaBio to support growth in Europe’s biotech sector
Updated: 2 days ago
Sligo, Ireland, 29 October 2026 – PRONAV Clinical is delighted to announce that it has joined EuropaBio as an Associate Member. EuropaBio is Europe’s largest biotechnology group, founded in 1996 to represent the interests of the biotechnology ecosystem across sectors. Its vision is a healthy, sustainable and competitive Europe, delivered through biotechnology innovation applied across industries. Its mission is to build the EU, national and global frameworks that allow this critical technology to reach its full potential, and we’re thrilled to be part of that effort.
PRONAV Clinical, a specialist in clinical trial supply chain services, is trusted by emerging biotech and biopharma companies around the world to accelerate and de-risk the delivery of their new therapies from manufacturing to early-phase clinical trials. That covers everything from managing their multi-nodal supply chain and performing complex GMP secondary packaging activities to QP batch certification, import/export compliance, EU and US regulatory strategy, and end-to-end supply chain visibility through our PROMAP platform.
Joining EuropaBio gives the PRONAV Clinical team a front-row seat to the development and rollout of the European Biotech Act, and a chance to share what we’ve learned in clinical supply with fellow members. We’re also looking forward to getting more involved in the European biotech community and helping the indigenous biotech industry grow, especially here in Ireland.
Jim Kernan, CEO of PRONAV Clinical, said: “We couldn’t be more excited to join EuropaBio. European biotech is in a really exciting place right now, and our clients are working on the therapies that will make a real difference to patients. We want to help them get from the lab to the clinic smoothly, and we share EuropaBio’s mission to build the frameworks that let this critical technology reach people across sectors. We can’t wait to get stuck in and help drive growth in the European biotech market.”
Dr. Claire Skentelbery, Director General of EuropaBio, said: “We are delighted to welcome Jim and the team into EuropaBio. We have a shared mission to see European clinical trials and supply chains working for patients and innovators and look forward to a busy year!”
